Panaji Journal

Chronic Obstructive Pulmonary Disease Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Sanofi, RegeneronPharmaceuticals, Verona PharmaPLC

 Breaking News
  • No posts were found

Chronic Obstructive Pulmonary Disease Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Sanofi, RegeneronPharmaceuticals, Verona PharmaPLC

November 17
20:05 2022
Chronic Obstructive Pulmonary Disease Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Sanofi, RegeneronPharmaceuticals, Verona PharmaPLC
The Chronic Obstructive Pulmonary Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Obstructive Pulmonary Disease pipeline products will significantly revolutionize the Chronic Obstructive Pulmonary Disease market dynamics.

DelveInsight’s “Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Obstructive Pulmonary Disease, historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Chronic Obstructive Pulmonary Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Chronic Obstructive Pulmonary Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Obstructive Pulmonary Disease Market Insights

 

Chronic Obstructive Pulmonary Disease Overview

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

 

Some of the key facts of the Chronic Obstructive Pulmonary Disease Market Report: 

  • The Chronic Obstructive Pulmonary Disease market size was valued at USD 12,134 Million in the year 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The Diagnosed prevalent population of COPD in the 7MM was 31,730,590 in 2020. These cases of Chronic Obstructive Pulmonary Disease (COPD) in the 7MM is expected to increase throughout the study period, i.e., 2019-32
  • The estimates suggest higher diagnosed prevalence of COPD in the United States with 17,455,605 diagnosed cases in 2020
  • Key Chronic Obstructive Pulmonary Disease Companies: Sanofi, RegeneronPharmaceuticals, Verona PharmaPLC, and others
  • Key Chronic Obstructive Pulmonary Disease Therapies: Itepekimab(SAR440340/REGN3500/Anti-IL-33 mAb), Ensifentrine(RPL554), Dupixent (Dupilumab), and others
  • The Chronic Obstructive Pulmonary Disease epidemiology based on gender analyzed that the majority of cases of COPD are female as compared to male, in the United States

 

Get a Free sample for the Chronic Obstructive Pulmonary Disease Market Report 

 

Key benefits of the Chronic Obstructive Pulmonary Disease Market report:

  1. Chronic Obstructive Pulmonary Disease market report covers a descriptive overview and comprehensive insight of the Chronic Obstructive Pulmonary Disease Epidemiology and Chronic Obstructive Pulmonary Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Chronic Obstructive Pulmonary Disease market report provides insights on the current and emerging therapies.
  3. Chronic Obstructive Pulmonary Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Chronic Obstructive Pulmonary Disease market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Chronic Obstructive Pulmonary Disease market.

 

Download the report to understand which factors are driving Chronic Obstructive Pulmonary Disease epidemiology trends @ Chronic Obstructive Pulmonary Disease Epidemiological Insights 

 

Chronic Obstructive Pulmonary Disease Market  

The dynamics of the Chronic Obstructive Pulmonary Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“COPD is often underdiagnosed or misdiagnosed and subsequently undertreated or mistreated. Out of total cases, very few cases are identified. A contributing factor to underdiagnoses is the failure of physicians and patients to recognize the significance of symptoms. Misdiagnosis of COPD is also common, with many patients being labeled as having smoker’s cough, asthma, or a lower respiratory tract infection.”

Chronic Obstructive Pulmonary Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Chronic Obstructive Pulmonary Disease Epidemiology Segmentation:

The Chronic Obstructive Pulmonary Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Chronic Obstructive Pulmonary Disease
  • Prevalent Cases of Chronic Obstructive Pulmonary Disease by severity
  • Gender-specific Prevalence of Chronic Obstructive Pulmonary Disease
  • Diagnosed Cases of Episodic and Chronic Chronic Obstructive Pulmonary Disease

 

Chronic Obstructive Pulmonary Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Obstructive Pulmonary Disease market or expected to get launched during the study period. The analysis covers Chronic Obstructive Pulmonary Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Obstructive Pulmonary Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Chronic Obstructive Pulmonary Disease market share @ Chronic Obstructive Pulmonary Disease market forecast 

 

Chronic Obstructive Pulmonary Disease Therapies and Key Companies

  • Itepekimab(SAR440340/REGN3500/Anti-IL-33 mAb): Sanofi/RegeneronPharmaceuticals
  • Ensifentrine(RPL554): Verona PharmaPLC
  • Dupixent (Dupilumab): Regeneron Pharmaceuticals/Sanofi

 

Chronic Obstructive Pulmonary Disease Market Drivers

  • Increasing prevalence of COPD
  • Emergence in development of emerging therapies
  • Personalized treatments
  • Entry of ‘Act earlier’ concept in the market
  • Improvement in diagnostic techniques
  • Growing demand for fixed-dose combinations

 

Scope of the Chronic Obstructive Pulmonary Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Chronic Obstructive Pulmonary Disease Companies: Sanofi, RegeneronPharmaceuticals, Verona PharmaPLC, and others
  • Key Chronic Obstructive Pulmonary Disease Therapies: Itepekimab(SAR440340/REGN3500/Anti-IL-33 mAb), Ensifentrine(RPL554), Dupixent (Dupilumab), and others
  • Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies
  • Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Chronic Obstructive Pulmonary Disease Unmet Needs, KOL’s views, Analyst’s views, Chronic Obstructive Pulmonary Disease Market Access and Reimbursement 

 

Chronic Obstructive Pulmonary Disease Market Barriers

  • Late recognition of COPD
  • High cost of treatment
  • Challenges in existing therapies
  • Patient-related barriers
  • Drug failure
  • Availability of generics

 

Table of Contents 

1. Chronic Obstructive Pulmonary Disease Market Report Introduction

2. Executive Summary for Chronic Obstructive Pulmonary Disease

3. SWOT analysis of Chronic Obstructive Pulmonary Disease

4. Chronic Obstructive Pulmonary Disease Patient Share (%) Overview at a Glance

5. Chronic Obstructive Pulmonary Disease Market Overview at a Glance

6. Chronic Obstructive Pulmonary Disease Disease Background and Overview

7. Chronic Obstructive Pulmonary Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Obstructive Pulmonary Disease 

9. Chronic Obstructive Pulmonary Disease Current Treatment and Medical Practices

10. Chronic Obstructive Pulmonary Disease Unmet Needs

11. Chronic Obstructive Pulmonary Disease Emerging Therapies

12. Chronic Obstructive Pulmonary Disease Market Outlook

13. Country-Wise Chronic Obstructive Pulmonary Disease Market Analysis (2019–2032)

14. Chronic Obstructive Pulmonary Disease Market Access and Reimbursement of Therapies

15. Chronic Obstructive Pulmonary Disease Market Drivers

16. Chronic Obstructive Pulmonary Disease Market Barriers

17.  Chronic Obstructive Pulmonary Disease Appendix

18. Chronic Obstructive Pulmonary Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Chronic Obstructive Pulmonary Disease treatment, visit @ Chronic Obstructive Pulmonary Disease Medications  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles